Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:OCAT

Ocata Therapeutics (OCAT) Stock Price, News & Analysis

Ocata Therapeutics logo

About Ocata Therapeutics Stock (NASDAQ:OCAT)

Key Stats

Today's Range
$8.47
$8.47
50-Day Range
N/A
52-Week Range
$3.06
$8.71
Volume
N/A
Average Volume
656,469 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Ocata Therapeutics, Inc., formerly Advanced Cell Technology, Inc., is a biotechnology company focused on the development and commercialization of Regenerative Ophthalmology therapeutics. The Company's advanced products are in clinical trials for the treatment of Stargardt's macular degeneration, dry age-related macular degeneration, and myopic macular degeneration. The Company is also developing several pre-clinical terminally differentiated-cell therapies for the treatment of other ocular disorders. Additionally, it has a number of pre-clinical stage assets in disease areas outside the field of ophthalmology, including autoimmune, inflammatory and wound healing-related disorders.

Receive OCAT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ocata Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

OCAT Stock News Headlines

Donald Trump can’t save you from this crisis
Elon Musk: “This Is The Most Destructive Force In History” Elon Musk claims a terrifying new economic force will put millions of Americans out of work. The ripple effects could nudge the US economy into a catastrophic tailspin. If this happens, you need to be prepared. That’s why a former Trump advisor is sharing his contingency plan with the public. What is Musk talking about?
Induced Pluripotent Stem Cells Market by 2031
See More Headlines

OCAT Stock Analysis - Frequently Asked Questions

Ocata Therapeutics (NASDAQ:OCAT) released its quarterly earnings results on Thursday, August, 6th. The biotechnology company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.19) by $0.01. The biotechnology company had revenue of $0.04 million for the quarter.

Based on aggregate information from My MarketBeat watchlists, some other companies that Ocata Therapeutics investors own include Antares Pharma (ATRS), Anavex Life Sciences (AVXL), Sarepta Therapeutics (SRPT), Athersys (ATHX), Prospect Capital (PSEC), Bristol-Myers Squibb (BMY) and Conatus Pharmaceuticals (CNAT).

Company Calendar

Last Earnings
8/06/2015
Today
11/22/2024

Industry, Sector and Symbol

Sector
N/A
Industry
N/A
Sub-Industry
N/A
Current Symbol
NASDAQ:OCAT
Previous Symbol
OTCMKTS:ACTC
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

This page (NASDAQ:OCAT) was last updated on 11/22/2024 by MarketBeat.com Staff
From Our Partners